These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32214228)

  • 21. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
    Schüle S; Renner M; Longhurst S; Narayanan G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy Briefs.
    Philippidis A
    Hum Gene Ther Clin Dev; 2018 Dec; 29(4):172-175. PubMed ID: 30576249
    [No Abstract]   [Full Text] [Related]  

  • 24. Maximum vs minimum harmonization: what to expect from the institutional and legal battles in the EU on gene editing technologies.
    Purnhagen KP; Wesseler JH
    Pest Manag Sci; 2019 Sep; 75(9):2310-2315. PubMed ID: 30714289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring Solutions to Foster ATMP Development and Access to Patients in Europe.
    Salvatore V
    Eur J Health Law; 2020 May; 27(3):259-273. PubMed ID: 33652396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How bans on germline editing deprive patients with mitochondrial disease.
    Cohen IG; Adashi EY; Ravitsky V
    Nat Biotechnol; 2019 Jun; 37(6):589-592. PubMed ID: 31110356
    [No Abstract]   [Full Text] [Related]  

  • 28. Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.
    De Wert G; Heindryckx B; Pennings G; Clarke A; Eichenlaub-Ritter U; van El CG; Forzano F; Goddijn M; Howard HC; Radojkovic D; Rial-Sebbag E; Dondorp W; Tarlatzis BC; Cornel MC;
    Eur J Hum Genet; 2018 Apr; 26(4):450-470. PubMed ID: 29326429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Crispr Future for Gene-Editing Regulation: a Proposal for an Updated Biotechnology Regulatory System in an Era of Human Genomic Editing.
    Tomlinson T
    Fordham Law Rev; 2018 Oct; 87(1):437-83. PubMed ID: 30296034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based Products.
    Bachtarzi H; Farries T
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):114-128. PubMed ID: 31111736
    [No Abstract]   [Full Text] [Related]  

  • 32. The Next Phase of Human Gene-Therapy Oversight.
    Collins FS; Gottlieb S
    N Engl J Med; 2018 Oct; 379(15):1393-1395. PubMed ID: 30110242
    [No Abstract]   [Full Text] [Related]  

  • 33. Genome Editing, Ethics, and Politics.
    Gabel I; Moreno J
    AMA J Ethics; 2019 Dec; 21(12):E1105-1110. PubMed ID: 31876477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR plants now subject to tough GM laws in European Union.
    Callaway E
    Nature; 2018 Aug; 560(7716):16. PubMed ID: 30065322
    [No Abstract]   [Full Text] [Related]  

  • 35. The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.
    Mahalatchimy A; Rial-Sebbag E; Tournay V; Faulkner A
    J Law Soc; 2012; 39(1):131-49. PubMed ID: 22530249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidance for human somatic cell therapy and gene therapy. March 1998. Center for Biologics Evaluation and Research, Food and Drug Administration.
    Hum Gene Ther; 1998 Jul; 9(10):1513-24. PubMed ID: 9681422
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of unregulated stem-cell based medicinal products.
    Committee for Advanced Therapies and CAT Scientific Secretariat
    Lancet; 2010 Aug; 376(9740):514. PubMed ID: 20709228
    [No Abstract]   [Full Text] [Related]  

  • 40. Guidance for human somatic cell therapy and gene therapy.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.
    Hum Gene Ther; 2001 Feb; 12(3):303-14. PubMed ID: 11177566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.